Skip to main content

Medtronic plc

For the period ended Oct 15, 2026. Filed Aug 17, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Oct 15, 2026 · Filed Aug 17, 2026

MDT$101.80-2.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

☒Filed by the Registrant☐Filed by a Party other than the Registrant
Check the appropriate box:
☐Preliminary Proxy Statement
☐CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive Additional Materials
☐Soliciting Material Pursuant to §240.14a-12

®

Medtronic plc

(Name of Registrant as specified in its charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):
☒No fee required.
☐Fee paid previously with preliminary materials.
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

2022 Proxy Statement and Notice of Annual Meeting of Shareholders

PROXY

STATEMENT

and Notice of 2026 Annual General Meeting of Shareholders

Thursday, October 15, 2026 -8:00 a.m. local time - Galway, Ireland

Notice of Annual General Meeting

Thursday, October 15, 2026

8:00 a.m. local time

The Galmont Hotel & Spa, Lough Atalia Rd., Galway, H91 CYN3, Ireland

MEETING AGENDA

  1. Electing, by separate resolutions, the twelve director nominees named in the proxy statement to hold office until the 2027 Annual General Meeting of Medtronic plc (Medtronic or the Company);

  2. Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP (PricewaterhouseCoopers) as the Company’s independent auditor for the fiscal year ending April 30, 2027 (fiscal year 2027 or FY27) and authorizing, in a binding vote, the Board of Directors (the Board), acting through the Audit Committee, to set the auditor’s remuneration;

  3. Approving, on an advisory basis, the Company’s executive compensation;

  4. Renewing the Board of Directors’ authority to issue shares under Irish law;

  5. Renewing the Board of Directors’ authority to opt out of pre-emption rights under Irish law;

  6. Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares;

  7. Receiving and considering the Company’s Irish Statutory Financial Statements for the fiscal year ended April 24, 2026 (fiscal year 2026 or FY26) and the reports of the directors and auditors thereon, and reviewing the affairs of the Company; and

  8. Transacting any other business that may properly come before the meeting and any adjournments or postponements thereof.

Proposals 1, 2, 3, 4, and 6 above are ordinary resolutions requiring a simple majority of the votes cast at the meeting to be approved. Proposal 5 is considered a special resolution requiring at least 75% of the votes cast at the meeting to be approved. All proposals are more fully described in the proxy statement. There is no requirement under Irish law that Medtronic’s Irish Statutory Financial Statements for fiscal year 2026, or the directors’ and auditor’s reports thereon, be approved by the shareholders, and no such approval will be sought at the 2026 Annual General Meeting of the Company (Annual General Meeting).

RECORD DATE

Shareholders of record at NYSE market close on August 21, 2026, will be entitled to vote at the Annual General Meeting.

ONLINE PROXY DELIVERY AND VOTING

As permitted by the U.S. Securities and Exchange Commission (the SEC), we are making this proxy statement, the Company’s 2026 Annual Report to Shareholders, and our Irish Statutory Financial Statements available to our shareholders electronically via the Internet. We believe electronic delivery expedites your receipt of materials, reduces the environmental impact of our Annual General Meeting, and reduces costs significantly. The Notice Regarding Internet Availability of Proxy Materials (the Notice) contains instructions on how you can access the proxy materials and how to vote online. If you receive the Notice by mail, you will not receive a printed copy of the proxy materials unless you request one in accordance with the instructions provided in the Notice. The Notice will be mailed to shareholders on or about September 3, 2026.

ADMISSION TO THE ANNUAL GENERAL MEETING

If you wish to attend the Annual General Meeting, you must be a shareholder on the record date and either request an admission ticket in advanceby visitingwww.proxyvote.com and following the instructions provided (you will need the control number included on your proxy card, voter instruction form or Notice), or bring proof of ownership of ordinary shares to the meeting. Tickets will be issued to registered and beneficial owners and to one guest accompanying each registered or beneficial owner.

August 17, 2026

By Order of the Board of Directors,

/s/ Michelle Quinn

Michelle Quinn

Executive Vice President, General Counsel and Secretary

Medtronic plc

Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting of Shareholders to be held on October 15, 2026: The proxy statement, the Company’s 2026 Annual Report to Shareholders, and our Irish Statutory Financial Statements for fiscal year 2026, are available atwww.proxyvote.com.

YOUR VOTE IS IMPORTANT. WE ENCOURAGE YOU TO VOTE.

If possible, please vote your shares over the internet using the instructions found in the Notice. Alternatively, you may request a printed copy of the proxy materials and vote using the toll-free telephone number on the proxy card or by marking, signing, dating and mailing your proxy card in the postage-paid envelope that will be provided. Voting by any of these methods will not limit your right to vote during the 2026 Annual General Meeting. All proxies will be forwarded to the Company’s registered office electronically.Under New York Stock Exchange (NYSE) rules, if you hold your shares in “street” name through a brokerage account, your broker will NOT be able to vote your shares on non-routine matters being considered at the 2026 Annual General Meeting unless you have given instructions to your broker prior to the meeting on how to vote your shares. Proposals 1 and 3 are considered non-routine matters under NYSE rules. This means that you must give specific voting instructions to your broker on how to vote your shares so that your vote can be counted.

Table of Contents

PROXY SUMMARY1REPORT OF THE AUDIT COMMITTEE76
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS6AUDIT AND NON-AUDIT FEES77
PROPOSAL 1Election of Directors9PROPOSAL 2Ratifying the Appointment of Independent Auditor and Authorizing the Audit Committee to Set Auditor Remuneration78
Directors and Nominees10
CORPORATE GOVERNANCE16PROPOSAL 3Advisory Resolution to Approve Named Executive Officer Compensation (Say-On-Pay)79
Corporate Governance Principles16
Board Performance Evaluations16
Lead Independent Director and Chairman; Executive Sessions16
Board Role in Risk Oversight17PROPOSAL 4Renewal of the Board’s Authority to Issue Shares Under Irish Law80
Compensation Risk Assessment18
Committees of the Board and Meetings22
Director Independence27
Related Party Transactions and Other Matters27PROPOSAL 5Renewal of the Board Authority to Opt Out of Statutory Pre-Emption Rights Under Irish Law81
Complaint Procedure; Communications with Directors28
Codes of Conduct28
Director Compensation29
Management32PROPOSAL 6Authorization of the Company and Any Subsidiary of the Company to Make Overseas Market Purchases of Medtronic Ordinary Shares83
SHARE OWNERSHIP INFORMATION35
Significant Shareholders35
Beneficial Ownership of Management35
COMPENSATION DISCUSSION AND ANALYSIS37QUESTIONS AND ANSWERS ABOUT THE ANNUAL GENERAL MEETING84
Executive Summary38
Process41Voting by Proxy84
Fiscal Year 2026 Compensation Program Designs44How Proxies Will Be Voted84
Fiscal Year 2026 Compensation Decisions45Voting at the Meeting84
Executive Compensation Governance Practices and Policies51Admission to the Meeting85
Other Benefits and Perquisites53
OTHER INFORMATION86
COMPENSATION AND TALENT COMMITTEE REPORT56Expenses of Solicitation86
Shareholder Proposals and Director Nominations86
EXECUTIVE COMPENSATION57Delivery of Documents to Shareholders Sharing an Address86
2026 Summary Compensation Table57Other87
2026 Grants of Plan-Based Awards60
2026 Awards at Fiscal Year End62APPENDIX A — Financial and Non-GAAP ReconciliationsA-1
2026 Option Exercises and Stock Vested64
2026 Pension Benefits65
2026 Nonqualified Deferred Compensation66
Potential Payments Upon Termination or Change of Control68
Equity Compensation Plan Information70
2026 CEO Pay Ratio71
2026 Pay Versus Performance71
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.